^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    perzebertinib (RG6596)

    i
    Other names: RG6596, ZN-A-1041, ZN-1041, RG 6596, ZN 1041, ZN A 1041, RG-6596, ZN1041, ZNA1041, RO7771950, RO-7771950
    Company:
    Roche, Suzhou Zanrong
    Drug class:
    HER2 inhibitor
    Related drugs:
    4d
    A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants (clinicaltrials.gov)
    P1, N=48, Recruiting, Genentech, Inc. | Trial completion date: Feb 2026 --> Aug 2026 | Trial primary completion date: Feb 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    perzebertinib (RG6596)
    10d
    A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=210, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • perzebertinib (RG6596)
    17d
    BReNNA: RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive (clinicaltrials.gov)
    P2/3, N=650, Not yet recruiting, Hoffmann-La Roche
    New P2/3 trial
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib) • perzebertinib (RG6596)
    2ms
    A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants (clinicaltrials.gov)
    P1, N=48, Recruiting, Genentech, Inc.
    New P1 trial
    |
    perzebertinib (RG6596)
    3ms
    A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=210, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Oct 2026 --> Jul 2026 | Trial primary completion date: Oct 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 positive
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • perzebertinib (RG6596)
    5ms
    A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on ZN-A-1041 Tablet(s) in Healthy Participants (clinicaltrials.gov)
    P1, N=18, Completed, Genentech, Inc. | Recruiting --> Completed | N=66 --> 18 | Trial completion date: Oct 2025 --> Jul 2025 | Trial primary completion date: Oct 2025 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    perzebertinib (RG6596)
    6ms
    A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=210, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Phase classification: P1 --> P1/2
    Enrollment closed • Phase classification
    |
    HER-2 positive
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • perzebertinib (RG6596)
    7ms
    ZN-1041-101: Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=61, Completed, Suzhou Zanrong Pharma Limited | Recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • capecitabine • perzebertinib (RG6596)
    8ms
    A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on ZN-A-1041 Tablet(s) in Healthy Participants (clinicaltrials.gov)
    P1, N=66, Recruiting, Genentech, Inc.
    New P1 trial
    |
    perzebertinib (RG6596)
    over1year
    A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=210, Recruiting, Suzhou Zanrong Pharma Limited | Trial completion date: Oct 2024 --> Oct 2026 | Trial primary completion date: Oct 2023 --> Oct 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 positive
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • perzebertinib (RG6596)
    over2years
    Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=84, Recruiting, Suzhou Zanrong Pharma Limited | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • capecitabine • perzebertinib (RG6596)
    over5years
    Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=84, Recruiting, Suzhou Zanrong Pharma Limited | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    capecitabine • perzebertinib (RG6596)